
Which Clinical Trial Is Right for Your Patient?





A clinical study evaluating elacestrant in patients with **CDK4/6 inhibitor-naive** ER+, HER2- **metastatic breast cancer**.³

Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). In ER positive (ER+) HER2-negative (HER2-) breast cancer cells, elacestrant inhibited 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.⁴

The information above is not intended for promotional or marketing purposes. The safety and efficacy of investigational uses of marketed products have not been established and marketing approval has not been granted by regulatory authorities.



For more information about the study design, objectives, and eligibility criteria visit **ClinicalTrials.gov**.

JoinTheClinicalTrial.com

CDK4/6, cyclin-dependent kinase 4 and 6; ER, estrogen receptor; ER+, estrogen receptor-positive; *ESR1*, estrogen receptor 1; HER2-, human epidermal growth factor receptor 2-negative.

- 1. ClinicalTrials.gov NCT05563220.
- ClinicalTrials.gov NCT05386108.
 ClinicalTrials.gov NCT05596409.
- ORSERDU[®] Prescribing Information. New York, NY: Stemline Therapeutics, Inc., a Menarini Group Company; 2024.

ORSERDU® is a registered trademark of the Menarini Group.

© 2024 - The Menarini Group. All rights reserved. 06/2024 MAT-US-ELA-00374



